RYTM
Rhythm Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.12B
P/E Ratio
—
EPS
$-3.13
Beta
1.92
52W High
$122.20
52W Low
$60.70
50-Day MA
$87.82
200-Day MA
$98.04
Dividend Yield
—
Profit Margin
-93.30%
Forward P/E
—
PEG Ratio
—
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $217.16M |
| Gross Profit (TTM) | $194.16M |
| EBITDA | $-196.17M |
| Operating Margin | -87.10% |
| Return on Equity | -101.20% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $3.28 |
| Book Value | $1.80 |
| Price-to-Book | 48.92 |
| Price-to-Sales (TTM) | 27.84 |
| EV/Revenue | 26.67 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83.80% |
| Shares Outstanding | $68.59M |
| Float | $55.70M |
| % Insiders | 0.77% |
| % Institutions | 109.98% |
Historical Volatility
HV 10-Day
36.49%
HV 20-Day
42.19%
HV 30-Day
52.64%
HV 60-Day
52.17%
HV Rank
70.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($138.20 target)
4
Strong Buy11
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026